Metacrine Broadens Management Team with Two Key Hires
17 avr. 2018 08h00 HE
|
Metacrine
SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
02 avr. 2018 10h20 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2018 (GLOBE NEWSWIRE) --
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that...
Immuron Granted US Patent for NASH Treatment
15 nov. 2017 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
18 août 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuing this press release to...
Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
13 juin 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and...
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
15 mai 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., May 15, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
25 avr. 2017 08h00 HE
|
Galectin Therapeutics
NORCROSS, Ga., April 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin...
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
18 avr. 2017 08h00 HE
|
Galectin Therapeutics
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN),...
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU
23 mars 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be...
Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
07 oct. 2016 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...